Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

PURPOSE: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Solomon, Benjamin J., Shaw, Alice T., Hashigaki, Satoshi, Ohki, Emiko, Usari, Tiziana, Paolini, Jolanda, Polli, Anna, Wilner, Keith D., Mok, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984/
https://www.ncbi.nlm.nih.gov/pubmed/28701030
http://dx.doi.org/10.4143/crt.2017.280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984/
https://www.ncbi.nlm.nih.gov/pubmed/28701030
http://dx.doi.org/10.4143/crt.2017.280

Ejemplares similares